Table 5 Ongoing clinical trials of immune-checkpoint inhibitors combined with non-cytotoxic agents
From: Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
Clinical trial ID | Phase | Setting | Regimen | Endpoint |
|---|---|---|---|---|
NCT03041311 | II | 1st line | CE plus atezolizumab +/− Trilaciclib | OS AEs |
NCT02922764 | I | 2nd line (solid tumors) | RGX-104 +/− Nivolumab | MTD ORR PFS |
NCT02712905 | I/II | ≥ 2nd line (solid tumors) | INCB059872 plus Nivolumab (part 3) | AEs |
NCT03126110 | I/II | ≥ 2nd line | INCAGN01876 plus nivolumab/ipilimumab/nivo+ipi | AEs ORR |
NCT03241173 | I/II | ≥ 2nd line | INCAGN01949 plus nivolumab/ipilimumab/nivo+ipi | AEs ORR |
NCT03026166 | I/II | ≥ 2nd line | Rova-T plus Nivolumab +/− ipilimumab | DLT |
NCT03085849 | I | 2nd line | SGI-110 followed by Durvalumab plus Tremelimumab | MTD |
NCT02734004 (MEDIOLA) | I/II | 2nd line | Durvalumab plus olaparib | DCR ORR AEs |
NCT02554812 | Ib/II | ≥ 2nd line | Avelumab plus utomilumab | DLT OR |